Immune treatments for alcohol use disorder: A translational framework

• Published in: Brain, behavior, and immunity behavior, and immunity, 2021-10, Vol.97, p.349-364
• Main Authors: Meredith, Lindsay R., Burnette, Elizabeth M., Grodin, Erica N., Irwin, Michael R., Ray, Lara A.
• Format: Article
• Language: English
• Subjects: Addiction; Alcohol use disorder; Alcoholism - therapy; Animals; Ethanol; Heavy alcohol use; Humans; Immune system; Immune therapy; Inflammation; Medications development; Neuroimmune modulator; Neuroinflammation; Toll-Like Receptors
• ISSN: 0889-1591; 1090-2139
• DOI: 10.1016/j.bbi.2021.07.023

•Research implicates the immune system in development of alcohol use disorder (AUD).•Several treatments targeting the immune system show promise for treating AUD.•Translational focus on therapies’ biological and clinical plausibility is necessary.•Immune therapies demonstrate optimism in regard to promoting recovery from AUD. While the immune system is essential for survival, an excessive or prolonged inflammatory response, such as that resulting from sustained heavy alcohol use, can damage the host and contribute to psychiatric disorders. A growing body of literature indicates that the immune system plays a critical role in the development and maintenance of alcohol use disorder (AUD). As such, there is enthusiasm for treatments that can restore healthy levels of inflammation as a mechanism to reduce drinking and promote recovery. In this qualitative literature review, we provide a conceptual rationale for immune therapies and discuss progress in medications development for AUD focused on the immune system as a treatment target. This review is organized into sections based on primary signaling pathways targeted by the candidate therapies, namely: (a) toll-like receptors, (b) phosphodiesterase inhibitors, (c) peroxisome proliferator-activated receptors, (d) microglia and astrocytes, (e) other immune pharmacotherapies, and (f) behavioral therapies. As relevant within each section, we examine the basic biological mechanisms of each class of therapy and evaluate preclinical research testing the role of the therapy on mitigating alcohol-related behaviors in animal models. To the extent available, translational findings are reviewed with discussion of completed and ongoing randomized clinical trials and their findings to date. An applied and clinically focused approach is taken to identify the potential clinical applications of the various treatments reviewed. We conclude by delineating the most promising candidate treatments and discussing future directions by considering opportunities for immune treatment development and personalized medicine for AUD.